Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Matthew Burke Discusses Adverse Events

      March 5, 2014
      By Matthew Burke, MBA, RN, MSN, APRN-BC
      Article

      Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carcinoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.

      Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carcinoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.

      Burke says chemotherapy-related adverse events are usually limited to the time that the drug is in the patient’s body while immunotherapy agents cause modifications in the checkpoints of the immune system that may be permanent.

      Because the immune system is altered during treatment with immunotherapy agents, Burke says the severity of immunotherapy-related adverse events can be much worse than chemotherapy-related adverse events. Also, it is difficult to predict which patients will experience severe adverse events from immunotherapy treatment.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      4 experts in this video
      4 experts in this video
      4 experts in this video
      4 experts in this video
      Image of a woman with light brown hair wearing glasses with a blue background
      Image of a woman wearing glasses in front of a blue background
      Image of a woman with glasses in front of a blue background
      Image of a man in a suit smiling in front of an Oncology Nursing News background
      Related Content

      Photo of a woman with brown hair and bangs, surrounded by a blue border

      AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

      Michelle Kirschner, RN, MSN, ACNP, APRN-BC
      June 30th 2025
      Article

      Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC


      The Vitals Podcast

      Amber Pierce Underscores the Importance of 2-Step Verification With Relatlimab/Nivolumab

      Lindsay Fischer
      May 19th 2023
      Podcast

      Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.


      Green and pink model of a melanoma cell

      NCCN Guidelines Update Includes HEPZATO KIT for Uveal Melanoma

      Ashling Wahner
      February 25th 2025
      Article

      Updates to the NCCN guidelines recommend HEPZATO KIT for use in hepatic-dominant uveal melanoma as a Category 2A treatment option.


      the vitals

      Krista Rubin Breaks Down Best Practices With Tebentafusp for Uveal Melanoma

      Lindsay Fischer
      May 4th 2023
      Podcast

      Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.


      Blue image of kidneys with renal tubules highlighted in red

      Nivolumab Plus Cabozantinib Effective Long-Term for Advanced RCC

      Tim Cortese
      February 15th 2025
      Article

      Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.


      Line illustration of the bladder and prostate on a cerulean background

      Darolutamide-ADT Combination Lengthens rPFS in mHSPC Regardless of Disease Volume

      Kyle Doherty
      February 15th 2025
      Article

      Patients with metastatic hormone-sensitive prostate cancer experienced increase rPFS and other efficacy end points with darolutamide plus ADT.

      Related Content

      Photo of a woman with brown hair and bangs, surrounded by a blue border

      AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

      Michelle Kirschner, RN, MSN, ACNP, APRN-BC
      June 30th 2025
      Article

      Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC


      The Vitals Podcast

      Amber Pierce Underscores the Importance of 2-Step Verification With Relatlimab/Nivolumab

      Lindsay Fischer
      May 19th 2023
      Podcast

      Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.


      Green and pink model of a melanoma cell

      NCCN Guidelines Update Includes HEPZATO KIT for Uveal Melanoma

      Ashling Wahner
      February 25th 2025
      Article

      Updates to the NCCN guidelines recommend HEPZATO KIT for use in hepatic-dominant uveal melanoma as a Category 2A treatment option.


      the vitals

      Krista Rubin Breaks Down Best Practices With Tebentafusp for Uveal Melanoma

      Lindsay Fischer
      May 4th 2023
      Podcast

      Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.


      Blue image of kidneys with renal tubules highlighted in red

      Nivolumab Plus Cabozantinib Effective Long-Term for Advanced RCC

      Tim Cortese
      February 15th 2025
      Article

      Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.


      Line illustration of the bladder and prostate on a cerulean background

      Darolutamide-ADT Combination Lengthens rPFS in mHSPC Regardless of Disease Volume

      Kyle Doherty
      February 15th 2025
      Article

      Patients with metastatic hormone-sensitive prostate cancer experienced increase rPFS and other efficacy end points with darolutamide plus ADT.

      Latest Conference Coverage

      No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases

      Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break

      Genomic Changes May Drive Sotorasib KRAS G12C+ Combo Resistance in CRC

      Relacorilant/Nab-Paclitaxel Is Convenient, Safe in Ovarian Cancer

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.